Chris Pak

Chris Pak is Chairman and Chief Executive Officer of Molecular Targeting Technologies, Inc. (MTTI), a clinical-stage radiopharmaceutical company developing next-generation targeted cancer radiotherapies. With more than 30 years of biotechnology leadership, he previously served as a scientist and director at Centocor, where he led the development of innovative radiopharmaceutical and molecular imaging technologies prior to the company’s acquisition by Johnson & Johnson. Dr. Pak later secured an exclusive commercial license from the U.S. National Institutes of Health (NIH) for the Evans Blue albumin-binding technology, establishing MTTI’s proprietary radiotherapeutic platform. Under his leadership, MTTI has advanced its lead candidate, ¹⁷⁷Lu-EBTATE, through Phase I/II clinical studies, demonstrating encouraging safety and efficacy in 81 patients with neuroendocrine tumors and positioning EBTATE as a promising next-generation peptide receptor radionuclide therapy (PRRT).